Agios Pharmaceuticals (NASDAQ:AGIO) is up 13% premarket on light volume in reaction to data on the combination of Tibsovo (ivosidenib) and chemo agent azacitidine (Celgene’s Vidaza) in IDH1 mutation-positive AML patients. The results were presented at ASH in Orlando.
Results from 23 newly diagnosed participants in a Phase 1/2 study showed a 61% (n=14) complete response (CR) rate, increasing to 70% (n=16) if CRs with partial hematologic recovery were included. Median duration of CR had not been reached at data cutoff.
#ASH19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.